Sage Therapeutics Inc (NASDAQ: SAGE) kicked off on Friday, up 4.24% from the previous trading day, before settling in for the closing price of $6.61. Over the past 52 weeks, SAGE has traded in a range of $4.62-$13.47.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 3403.60%. While this was happening, its average annual earnings per share was recorded 46.19%. With a float of $55.09 million, this company’s outstanding shares have now reached $62.54 million.
Considering the fact that the conglomerate employs 353 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 81.37%, operating margin of -806.16%, and the pretax margin is -747.61%.
Sage Therapeutics Inc (SAGE) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Sage Therapeutics Inc is 12.03%, while institutional ownership is 89.89%. The most recent insider transaction that took place on Dec 10 ’24, was worth 41,441.
Sage Therapeutics Inc (SAGE) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around 46.19% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 36.05% during the next five years compared to 13.20% growth over the previous five years of trading.
Sage Therapeutics Inc (NASDAQ: SAGE) Trading Performance Indicators
Take a look at Sage Therapeutics Inc’s (SAGE) current performance indicators. Last quarter, stock had a quick ratio of 9.13. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 9.10.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -5.80, a number that is poised to hit -0.96 in the next quarter and is forecasted to reach -2.81 in one year’s time.
Technical Analysis of Sage Therapeutics Inc (SAGE)
Compared to the last year’s volume of 1.6 million, its volume of 0.79 million showed lagged in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 31.51%. Additionally, its Average True Range was 0.31.
During the past 100 days, Sage Therapeutics Inc’s (SAGE) raw stochastic average was set at 50.26%, which indicates a significant increase from 36.30% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 44.20% in the past 14 days, which was lower than the 66.58% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $7.45, while its 200-day Moving Average is $7.07. Nevertheless, the first resistance level for the watch stands at $7.03 in the near term. At $7.17, the stock is likely to face the second major resistance level. The third major resistance level sits at $7.41. If the price goes on to break the first support level at $6.65, it is likely to go to the next support level at $6.41. Now, if the price goes above the second support level, the third support stands at $6.27.
Sage Therapeutics Inc (NASDAQ: SAGE) Key Stats
The company with the Market Capitalisation of 431.46 million has total of 62,621K Shares Outstanding. Its annual sales at the moment are 41,240 K in contrast with the sum of -400,670 K annual income. Company’s last quarter sales were recorded 14,060 K and last quarter income was -62,210 K.
